Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Below 200-Day Moving Average – Here’s Why

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.91 and traded as low as $1.53. Aldeyra Therapeutics shares last traded at $1.55, with a volume of 471,861 shares changing hands.

Key Headlines Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Schall, Pomerantz, and others, reiterated that investors who bought ALDX between November 3, 2023 and March 16, 2026 may be eligible to participate in the class action before the May 29 deadline. Article Title
• Neutral Sentiment: Bronstein, Gewirtz & Grossman said a class action lawsuit has already been filed against Aldeyra and certain officers, alleging violations of federal securities laws and seeking damages for shareholders. Article Title
• Neutral Sentiment: Investors are also being urged by firms such as SueWallSt and the Schall Law Firm to review alleged shortcomings in Aldeyra’s disclosures, which keeps litigation risk in focus for the stock. Article Title

Analyst Ratings Changes

ALDX has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. HC Wainwright restated a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. Finally, Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Aldeyra Therapeutics presently has a consensus rating of “Hold” and an average target price of $5.50.

Aldeyra Therapeutics Price Performance

The business’s 50-day moving average price is $1.84 and its two-hundred day moving average price is $3.91. The company has a market capitalization of $93.50 million, a price-to-earnings ratio of -3.37 and a beta of 1.16.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. As a group, research analysts predict that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current year.

Insider Buying and Selling

In other Aldeyra Therapeutics news, Director Richard Douglas bought 70,000 shares of the stock in a transaction on Thursday, March 19th. The stock was purchased at an average price of $1.40 per share, with a total value of $98,000.00. Following the completion of the purchase, the director owned 195,000 shares in the company, valued at $273,000. The trade was a 56.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALDX. AQR Capital Management LLC increased its holdings in shares of Aldeyra Therapeutics by 275.4% during the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after buying an additional 1,081,257 shares in the last quarter. 683 Capital Management LLC increased its holdings in shares of Aldeyra Therapeutics by 86.6% during the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after buying an additional 710,000 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Aldeyra Therapeutics by 146.6% during the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock worth $1,459,000 after buying an additional 513,187 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Aldeyra Therapeutics by 61.9% during the third quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock worth $5,806,000 after buying an additional 425,245 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Aldeyra Therapeutics by 590.5% during the third quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company’s stock worth $2,036,000 after buying an additional 333,587 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.